Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas

Takeshi Shimamura, Michiie Sakamoto, Yoshinori Ino, Kazuaki Shimada, Tomoo Kosuge, Yasuto Sato, Katsuaki Tanaka, Hisahiko Sekihara, Setsuo Hirohashi

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Purpose: Galectin-3, a member of the β-galactoside-binding lectin family, has multiple biological functions including cell-cell interactions and cell-extracellular matrix adhesion, cellular proliferation, cellular differentiation, and apoptosis. The aim of this study was to determine the relationship of galectin-3 expression to clinicopathological findings and patient prognosis in ductal adenocarcinoma of the pancreas. Experimental Design: We examined galectin-3 expression in 104 surgically resected pancreatic ductal adenocarcinoma cases with stages I through IV using immunohistochemistry and investigated the relationship of it to overall survival. Results: Patients were divided into two groups: a low expression group, where <60% of tumor cells were positive; and a high expression group, where ≥60% of tumor cells were positive. Cases in the low expression group had a significant tendency to be at later stages, to have distant metastasis, and to have less differentiated tumors, compared with cases in the high expression group (P = 0.001 for stage, P = 0.001 for metastasis, and P = 0.006 for differentiation). Postoperative overall survival was worse in the low galectin-3 expression group than in the high galectin-3 expression group (P = 0.004). Multivariate analysis showed that the risk ratio of prognosis was 2.06 among patients in the low galectin-3 expression group compared with the high galectin-3 expression group (P = 0.006). Conclusions: Decreased expression of galectin-3 was associated with advanced stage, tumor de-differentiation, and metastasis in ductal adenocarcinoma of the pancreas. Galectin-3 expression might be a useful prognostic marker for survival in ductal adenocarcinoma of the pancreas.

Original languageEnglish
Pages (from-to)2570-2575
Number of pages6
JournalClinical Cancer Research
Volume8
Issue number8
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Galectin 3
Pancreas
Adenocarcinoma
Neoplasm Metastasis
Survival
Neoplasms
Cell-Matrix Junctions
Galactosides
Lectins
Cell Communication
Extracellular Matrix
Research Design
Multivariate Analysis
Immunohistochemistry
Odds Ratio
Cell Proliferation
Apoptosis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shimamura, T., Sakamoto, M., Ino, Y., Shimada, K., Kosuge, T., Sato, Y., ... Hirohashi, S. (2002). Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clinical Cancer Research, 8(8), 2570-2575.

Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. / Shimamura, Takeshi; Sakamoto, Michiie; Ino, Yoshinori; Shimada, Kazuaki; Kosuge, Tomoo; Sato, Yasuto; Tanaka, Katsuaki; Sekihara, Hisahiko; Hirohashi, Setsuo.

In: Clinical Cancer Research, Vol. 8, No. 8, 2002, p. 2570-2575.

Research output: Contribution to journalArticle

Shimamura, T, Sakamoto, M, Ino, Y, Shimada, K, Kosuge, T, Sato, Y, Tanaka, K, Sekihara, H & Hirohashi, S 2002, 'Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas', Clinical Cancer Research, vol. 8, no. 8, pp. 2570-2575.
Shimamura, Takeshi ; Sakamoto, Michiie ; Ino, Yoshinori ; Shimada, Kazuaki ; Kosuge, Tomoo ; Sato, Yasuto ; Tanaka, Katsuaki ; Sekihara, Hisahiko ; Hirohashi, Setsuo. / Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 8. pp. 2570-2575.
@article{47887ae4d06242138ae335bb24b64405,
title = "Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas",
abstract = "Purpose: Galectin-3, a member of the β-galactoside-binding lectin family, has multiple biological functions including cell-cell interactions and cell-extracellular matrix adhesion, cellular proliferation, cellular differentiation, and apoptosis. The aim of this study was to determine the relationship of galectin-3 expression to clinicopathological findings and patient prognosis in ductal adenocarcinoma of the pancreas. Experimental Design: We examined galectin-3 expression in 104 surgically resected pancreatic ductal adenocarcinoma cases with stages I through IV using immunohistochemistry and investigated the relationship of it to overall survival. Results: Patients were divided into two groups: a low expression group, where <60{\%} of tumor cells were positive; and a high expression group, where ≥60{\%} of tumor cells were positive. Cases in the low expression group had a significant tendency to be at later stages, to have distant metastasis, and to have less differentiated tumors, compared with cases in the high expression group (P = 0.001 for stage, P = 0.001 for metastasis, and P = 0.006 for differentiation). Postoperative overall survival was worse in the low galectin-3 expression group than in the high galectin-3 expression group (P = 0.004). Multivariate analysis showed that the risk ratio of prognosis was 2.06 among patients in the low galectin-3 expression group compared with the high galectin-3 expression group (P = 0.006). Conclusions: Decreased expression of galectin-3 was associated with advanced stage, tumor de-differentiation, and metastasis in ductal adenocarcinoma of the pancreas. Galectin-3 expression might be a useful prognostic marker for survival in ductal adenocarcinoma of the pancreas.",
author = "Takeshi Shimamura and Michiie Sakamoto and Yoshinori Ino and Kazuaki Shimada and Tomoo Kosuge and Yasuto Sato and Katsuaki Tanaka and Hisahiko Sekihara and Setsuo Hirohashi",
year = "2002",
language = "English",
volume = "8",
pages = "2570--2575",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas

AU - Shimamura, Takeshi

AU - Sakamoto, Michiie

AU - Ino, Yoshinori

AU - Shimada, Kazuaki

AU - Kosuge, Tomoo

AU - Sato, Yasuto

AU - Tanaka, Katsuaki

AU - Sekihara, Hisahiko

AU - Hirohashi, Setsuo

PY - 2002

Y1 - 2002

N2 - Purpose: Galectin-3, a member of the β-galactoside-binding lectin family, has multiple biological functions including cell-cell interactions and cell-extracellular matrix adhesion, cellular proliferation, cellular differentiation, and apoptosis. The aim of this study was to determine the relationship of galectin-3 expression to clinicopathological findings and patient prognosis in ductal adenocarcinoma of the pancreas. Experimental Design: We examined galectin-3 expression in 104 surgically resected pancreatic ductal adenocarcinoma cases with stages I through IV using immunohistochemistry and investigated the relationship of it to overall survival. Results: Patients were divided into two groups: a low expression group, where <60% of tumor cells were positive; and a high expression group, where ≥60% of tumor cells were positive. Cases in the low expression group had a significant tendency to be at later stages, to have distant metastasis, and to have less differentiated tumors, compared with cases in the high expression group (P = 0.001 for stage, P = 0.001 for metastasis, and P = 0.006 for differentiation). Postoperative overall survival was worse in the low galectin-3 expression group than in the high galectin-3 expression group (P = 0.004). Multivariate analysis showed that the risk ratio of prognosis was 2.06 among patients in the low galectin-3 expression group compared with the high galectin-3 expression group (P = 0.006). Conclusions: Decreased expression of galectin-3 was associated with advanced stage, tumor de-differentiation, and metastasis in ductal adenocarcinoma of the pancreas. Galectin-3 expression might be a useful prognostic marker for survival in ductal adenocarcinoma of the pancreas.

AB - Purpose: Galectin-3, a member of the β-galactoside-binding lectin family, has multiple biological functions including cell-cell interactions and cell-extracellular matrix adhesion, cellular proliferation, cellular differentiation, and apoptosis. The aim of this study was to determine the relationship of galectin-3 expression to clinicopathological findings and patient prognosis in ductal adenocarcinoma of the pancreas. Experimental Design: We examined galectin-3 expression in 104 surgically resected pancreatic ductal adenocarcinoma cases with stages I through IV using immunohistochemistry and investigated the relationship of it to overall survival. Results: Patients were divided into two groups: a low expression group, where <60% of tumor cells were positive; and a high expression group, where ≥60% of tumor cells were positive. Cases in the low expression group had a significant tendency to be at later stages, to have distant metastasis, and to have less differentiated tumors, compared with cases in the high expression group (P = 0.001 for stage, P = 0.001 for metastasis, and P = 0.006 for differentiation). Postoperative overall survival was worse in the low galectin-3 expression group than in the high galectin-3 expression group (P = 0.004). Multivariate analysis showed that the risk ratio of prognosis was 2.06 among patients in the low galectin-3 expression group compared with the high galectin-3 expression group (P = 0.006). Conclusions: Decreased expression of galectin-3 was associated with advanced stage, tumor de-differentiation, and metastasis in ductal adenocarcinoma of the pancreas. Galectin-3 expression might be a useful prognostic marker for survival in ductal adenocarcinoma of the pancreas.

UR - http://www.scopus.com/inward/record.url?scp=0036023418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036023418&partnerID=8YFLogxK

M3 - Article

C2 - 12171885

AN - SCOPUS:0036023418

VL - 8

SP - 2570

EP - 2575

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -